Pipeline AlzeCure enters collaboration agreement with QuantumCell ApS for NeuroRestore project PharmaTimesQuantumCell gains global rights to NeuroRestore platform in deal worth over USD 2.2 billionNeuroscienceRead full story pharminent July 1, 2026 (Last updated: July 2, 2026) PharmaTimes QuantumCell gains global rights to NeuroRestore platform in deal worth over USD 2.2 billion Neuroscience Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Eli Lilly and Regeneron among 7 companies picked for FDA PreCheck pilot programNext: Ipsen to buy Swiss biotech Memo Therapeutics in potential $800M deal Related Stories Pipeline Biogen trims Apellis pipeline and R&D team after $5.6bn takeover pharminent June 29, 2026 Pipeline Moderna looks out to R&D ‘horizons’ as 2028 break-even goal looms pharminent June 26, 2026 Pipeline Lundbeck to present new Vyepti and bocunebart data at EAN 2026 pharminent June 24, 2026
